{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "578a8365",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "c:\\Users\\Аскер\\Desktop\\LLM-based agent (Alzheimer's disease)\\.venv\\Lib\\site-packages\\tqdm\\auto.py:21: TqdmWarning: IProgress not found. Please update jupyter and ipywidgets. See https://ipywidgets.readthedocs.io/en/stable/user_install.html\n",
      "  from .autonotebook import tqdm as notebook_tqdm\n"
     ]
    }
   ],
   "source": [
    "from rag.rag import startRAG, answer_question, chat_update"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "8192dabb",
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "from dotenv import load_dotenv\n",
    "\n",
    "load_dotenv()\n",
    "\n",
    "api_key = os.environ.get(\"OPENROUTER_API_KEY\")\n",
    "db_path = \"db_collecting/chroma_artilcles\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "f5403f5e",
   "metadata": {},
   "outputs": [],
   "source": [
    "chat = []\n",
    "query_1 = \"What are potential targets for Alzheimer's disease treatment?\"\n",
    "query_2 = \"Are the targets druggable with small molecules, biologics, or other modalities?\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "6aafad30",
   "metadata": {},
   "outputs": [],
   "source": [
    "chat = chat_update(chat, \"user\", query_1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "e683d833",
   "metadata": {},
   "outputs": [],
   "source": [
    "identified_answer_chain, answer_chain, structurized_answer_chain, retriever = startRAG(db_path, api_key)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "8d362884",
   "metadata": {},
   "outputs": [],
   "source": [
    "chat, file_dict = answer_question(identified_answer_chain, answer_chain, structurized_answer_chain, retriever, chat)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "a76201c0",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The provided documents mention several potential therapeutic targets for Alzheimer's disease (AD). These include: \n",
      "*   **Modifiable risk factors:** Targeting these is crucial to prevent or delay AD (Associations of semaglutide with first‐time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real‐world data in the US, https://doi.org/10.1002/alz.14313). \n",
      "*   **Transthyretin (TTR)** and **Amyloid peptide (Ab)** systems (Targeting transthyretin in Alzheimer's disease: Drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer's disease, https://doi.org/10.1016/j.ejmech.2021.113847). \n",
      "*   **Microtubule-associated protein** \n",
      "*   **Anti-neuroinflammation** \n",
      "*   **Synaptic and neuroprotection** \n",
      "*   **Metabolism** \n",
      "*   **Neurogenesis** \n",
      "*   **Vascular system** \n",
      "*   **Epigenetic drugs** (Intelligent lesion blood–brain barrier targeting nano-missiles for Alzheimer's disease treatment by anti-neuroinflammation and neuroprotection, https://doi.org/10.1016/j.apsb.2022.02.001). \n",
      "*   **Disease-related genes** identified through transcriptomic data analysis (Multiomics Identification of Potential Targets for Alzheimer Disease and Antrocin as a Therapeutic Candidate, https://doi.org/10.3390/pharmaceutics13101555).\n"
     ]
    }
   ],
   "source": [
    "print(chat[-1][\"text\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "96267b2c",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'8.pdf': \"Associations of semaglutide with first‐time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real‐world data in the US\",\n",
       " '12.pdf': \"Targeting transthyretin in Alzheimer's disease: Drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer's disease\",\n",
       " '6.pdf': \"Intelligent lesion blood–brain barrier targeting nano-missiles for Alzheimer's disease treatment by anti-neuroinflammation and neuroprotection\",\n",
       " '21.pdf': 'Multiomics Identification of Potential Targets for Alzheimer Disease and Antrocin as a Therapeutic Candidate'}"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "file_dict"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "9a1c62c4",
   "metadata": {},
   "outputs": [],
   "source": [
    "chat = chat_update(chat, \"user\", query_2)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "42ed9478",
   "metadata": {},
   "outputs": [],
   "source": [
    "chat, file_dict = answer_question(identified_answer_chain, answer_chain, structurized_answer_chain, retriever, chat)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "a80b9379",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The provided documents indicate that Alzheimer's disease is being approached with various therapeutic strategies, including small molecule drugs and biologics. Specifically, the text mentions the development of nanodrug delivery systems loaded with small molecule drugs (rapamycin and TPPU) to target pathological areas in the brain ( “Hybrid Membrane‐Coated Nanoparticles for Precise Targeting and Synergistic Therapy in Alzheimer's Disease” [https://doi.org/10.1002/advs.202306675]). Additionally, the documents state that vaccines are being investigated as a new approach to treating AD by targeting key factors like tau protein and beta-amyloid plaques (“Natural acetylcholinesterase inhibitors: A multi-targeted therapeutic potential in Alzheimer's disease” [https://doi.org/10.1016/j.ejmcr.2024.100154]). Exosomes are also being investigated for treatment delivery (“Natural acetylcholinesterase inhibitors: A multi-targeted therapeutic potential in Alzheimer's disease” [https://doi.org/10.1016/j.ejmcr.2024.100154]). The documents also mention existing drugs like huperzine A, galantamine, physostigmine, and rivastigmine used clinically to treat Alzheimer’s disease (“Natural acetylcholinesterase inhibitors: A multi-targeted therapeutic potential in Alzheimer's disease” [https://doi.org/10.1016/j.ejmcr.2024.100154]).\n"
     ]
    }
   ],
   "source": [
    "print(chat[-1][\"text\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "651e606f",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'13.pdf': \"Hybrid Membrane‐Coated Nanoparticles for Precise Targeting and Synergistic Therapy in Alzheimer's Disease\",\n",
       " '2.pdf': \"Natural acetylcholinesterase inhibitors: A multi-targeted therapeutic potential in Alzheimer's disease\"}"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "file_dict"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "170a91d7",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "\"What therapeutic modalities (e.g., small molecules, biologics, vaccines, exosomes) are being investigated or used to target Alzheimer's disease?\""
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "user_query = (identified_answer_chain.invoke({\"chat_history\": str(chat), \"question\": chat[-1][\"text\"]})).strip()\n",
    "user_query"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "093ffed0",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(id='b99b6fc3-ebdb-41ea-b285-679e46c6286f', metadata={'id': 7, 'file': '2.pdf', 'link': 'https://doi.org/10.1016/j.ejmcr.2024.100154', 'title': \"Natural acetylcholinesterase inhibitors: A multi-targeted therapeutic potential in Alzheimer's disease\", 'type': 'introduction', 'year': 2024}, page_content='vaccines as a new approach to treating AD [ 24 ], targeting key factors like tau protein and beta-amyloid plaques. Developing drugs that can target multiple aspects of the disease simul -taneously is becoming more important. Exosomes, tiny vesicles that can cross the blood-brain barrier, are being investigated for their potential to deliver treatments directly to the brain for conditions like AD [ 25 ]. Our review article provides an overview of'),\n",
       " Document(id='96986312-5a98-4615-99d1-599c522885b6', metadata={'id': 35, 'year': 2021, 'title': \"Targeting transthyretin in Alzheimer's disease: Drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer's disease\", 'link': 'https://doi.org/10.1016/j.ejmech.2021.113847', 'type': 'result', 'file': '12.pdf'}, page_content=\"and from the literature were selected, so as they were either (i) known TTR binders, (ii) amyloid peptide binding ligands, or (iii) both, or (iv) compounds under study in clinical phases for the treatment of Alzheimer's disease. The use of the CARLSBAD software and database [64] allowed us to find privileged scaffolds with reported biological activity against both TTR and Ab systems. This scaffold hunting methodology allowed us to find a group\"),\n",
       " Document(id='4a5710b3-b194-4d7d-a921-4c29e8752a45', metadata={'link': 'https://doi.org/10.1016/j.jep.2022.115107', 'file': '7.pdf', 'title': \"Multi-target neuroprotective effects of herbal medicines for Alzheimer's disease\", 'id': 21, 'type': 'abstract', 'year': 2022}, page_content='The results extend the knowledge on the potential use of plant extracts to combat multifactorial disorders, giving new insights into therapeutic avenues for Alzheimer ’ s disease.'),\n",
       " Document(id='bf8f9820-7a45-4da2-a2d2-0a48550690d0', metadata={'type': 'abstract', 'file': '18.pdf', 'id': 51, 'title': \"A dual-targeted multifunctional nanoformulation for potential prevention and therapy of Alzheimer's disease\", 'link': 'https://doi.org/10.1016/j.xinn.2021.100160', 'year': 2021}, page_content='good biosafety, which has broad prospects for the early prevention, mild remission, and late treatment of AD, and is expected to be developed into personalized therapeutic drugs and health-care products for clinical AD in the future.'),\n",
       " Document(id='63176b44-f2ac-4079-be0e-a8d4c0e97c12', metadata={'type': 'result', 'title': 'A hybrid approach unveils drug repurposing candidates targeting an Alzheimer pathophysiology mechanism', 'id': 74, 'file': '26.pdf', 'link': 'https://doi.org/10.1016/j.patter.2021.100433', 'year': 2022}, page_content='identifying novel therapeutic strategies (1) A knowledge-based ‘‘cause-and-effect’’ disease model (here: Alzheimer disease) is initiated using manually curated information as well as standardized data from reputable repositories (see ‘‘The HBP’’ in results). (2) An entry point (primary target; here: pTau) associated with a pathophysiology mechanism of interest is selected, and upstream regulators (secondary interactors) modulating key elements')]"
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "docs_retrieved = retriever.invoke(user_query)\n",
    "docs_retrieved"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "d13afa66",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'\"The following therapeutic modalities are being investigated for Alzheimer\\'s disease (AD):\\n\\n*   **Vaccines:** Vaccines are being explored as a new approach to treating AD, targeting factors like tau protein and beta-amyloid plaques (\"Natural acetylcholinesterase inhibitors: A multi-targeted therapeutic potential in Alzheimer\\'s disease\", https://doi.org/10.1016/j.ejmcr.2024.100154).\\n*   **Small-molecule chaperones:** These are being investigated as disease-modifying drug candidates (\"Targeting transthyretin in Alzheimer\\'s disease: Drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer\\'s disease\", https://doi.org/10.1016/j.ejmech.2021.113847).\\n*   **Plant extracts:** Plant extracts are being investigated for their potential use in combating Alzheimer’s disease (\"Multi-target neuroprotective effects of herbal medicines for Alzheimer\\'s disease\", https://doi.org/10.1016/j.jep.2022.115107).\\n*   **Nanoformulations:** Dual-targeted multifunctional nanoformulations are being investigated for the potential prevention and therapy of AD (\"A dual-targeted multifunctional nanoformulation for potential prevention and therapy of Alzheimer\\'s disease\", https://doi.org/10.1016/j.xinn.2021.100160).\\n*   **Drugs targeting pTau:** Drugs targeting pTau are being investigated as a therapeutic strategy (\"A hybrid approach unveils drug repurposing candidates targeting an Alzheimer pathophysiology mechanism\", https://doi.org/10.1016/j.patter.2021.100433).\\n*   **Exosomes:** Exosomes are being investigated for their potential to deliver treatments directly to the brain for conditions like AD (\"Natural acetylcholinesterase inhibitors: A multi-targeted therapeutic potential in Alzheimer\\'s disease\", https://doi.org/10.1016/j.ejmcr.2024.100154).\"'"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "initial_answer = answer_chain.invoke({\"docs\": docs_retrieved, \"question\": user_query})\n",
    "initial_answer"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "4f53099f",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'message': 'The following therapeutic modalities are being investigated for Alzheimer\\'s disease (AD):\\n\\n*   **Vaccines:** Vaccines are being explored as a new approach to treating AD, targeting factors like tau protein and beta-amyloid plaques (\"Natural acetylcholinesterase inhibitors: A multi-targeted therapeutic potential in Alzheimer\\'s disease\", https://doi.org/10.1016/j.ejmcr.2024.100154).\\n*   **Small-molecule chaperones:** These are being investigated as disease-modifying drug candidates (\"Targeting transthyretin in Alzheimer\\'s disease: Drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer\\'s disease\", https://doi.org/10.1016/j.ejmech.2021.113847).\\n*   **Plant extracts:** Plant extracts are being investigated for their potential use in combating Alzheimer’s disease (\"Multi-target neuroprotective effects of herbal medicines for Alzheimer\\'s disease\", https://doi.org/10.1016/j.jep.2022.115107).\\n*   **Nanoformulations:** Dual-targeted multifunctional nanoformulations are being investigated for the potential prevention and therapy of AD (\"A dual-targeted multifunctional nanoformulation for potential prevention and therapy of Alzheimer\\'s disease\", https://doi.org/10.1016/j.xinn.2021.100160).\\n*   **Drugs targeting pTau:** Drugs targeting pTau are being investigated as a therapeutic strategy (\"A hybrid approach unveils drug repurposing candidates targeting an Alzheimer pathophysiology mechanism\", https://doi.org/10.1016/j.patter.2021.100433).\\n*   **Exosomes:** Exosomes are being investigated for their potential to deliver treatments directly to the brain for conditions like AD (\"Natural acetylcholinesterase inhibitors: A multi-targeted therapeutic potential in Alzheimer\\'s disease\", https://doi.org/10.1016/j.ejmcr.2024.100154).',\n",
       " 'sources': [{'title': \"Natural acetylcholinesterase inhibitors: A multi-targeted therapeutic potential in Alzheimer's disease\",\n",
       "   'file': '2.pdf'},\n",
       "  {'title': \"Targeting transthyretin in Alzheimer's disease: Drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer's disease\",\n",
       "   'file': '12.pdf'},\n",
       "  {'title': \"Multi-target neuroprotective effects of herbal medicines for Alzheimer's disease\",\n",
       "   'file': '7.pdf'},\n",
       "  {'title': \"A dual-targeted multifunctional nanoformulation for potential prevention and therapy of Alzheimer's disease\",\n",
       "   'file': '18.pdf'},\n",
       "  {'title': 'A hybrid approach unveils drug repurposing candidates targeting an Alzheimer pathophysiology mechanism',\n",
       "   'file': '26.pdf'}]}"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "result = structurized_answer_chain.invoke({\"initial_answer\": initial_answer, \"docs\": docs_retrieved})\n",
    "result"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "id": "76fb2d90",
   "metadata": {},
   "outputs": [],
   "source": [
    "message = dict(result)[\"message\"]\n",
    "sources_list = dict(result)[\"sources\"]\n",
    "    \n",
    "file_dict = {source.get(\"file\"): source.get(\"title\") for source in sources_list}\n",
    "\n",
    "chat = chat_update(chat, \"ai\", message)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "6a3c30fb",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'role': 'user',\n",
       "  'text': \"What are potential targets for Alzheimer's disease treatment?\"},\n",
       " {'role': 'ai',\n",
       "  'text': \"The provided documents mention several potential therapeutic targets for Alzheimer's disease (AD). These include: \\n*   **Modifiable risk factors:** Targeting these is crucial to prevent or delay AD (Associations of semaglutide with first‐time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real‐world data in the US, https://doi.org/10.1002/alz.14313). \\n*   **Transthyretin (TTR)** and **Amyloid peptide (Ab)** systems (Targeting transthyretin in Alzheimer's disease: Drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer's disease, https://doi.org/10.1016/j.ejmech.2021.113847). \\n*   **Microtubule-associated protein** \\n*   **Anti-neuroinflammation** \\n*   **Synaptic and neuroprotection** \\n*   **Metabolism** \\n*   **Neurogenesis** \\n*   **Vascular system** \\n*   **Epigenetic drugs** (Intelligent lesion blood–brain barrier targeting nano-missiles for Alzheimer's disease treatment by anti-neuroinflammation and neuroprotection, https://doi.org/10.1016/j.apsb.2022.02.001). \\n*   **Disease-related genes** identified through transcriptomic data analysis (Multiomics Identification of Potential Targets for Alzheimer Disease and Antrocin as a Therapeutic Candidate, https://doi.org/10.3390/pharmaceutics13101555).\"},\n",
       " {'role': 'user',\n",
       "  'text': 'Are the targets druggable with small molecules, biologics, or other modalities?'},\n",
       " {'role': 'ai',\n",
       "  'text': \"The provided documents indicate that Alzheimer's disease is being approached with various therapeutic strategies, including small molecule drugs and biologics. Specifically, the text mentions the development of nanodrug delivery systems loaded with small molecule drugs (rapamycin and TPPU) to target pathological areas in the brain ( “Hybrid Membrane‐Coated Nanoparticles for Precise Targeting and Synergistic Therapy in Alzheimer's Disease” [https://doi.org/10.1002/advs.202306675]). Additionally, the documents state that vaccines are being investigated as a new approach to treating AD by targeting key factors like tau protein and beta-amyloid plaques (“Natural acetylcholinesterase inhibitors: A multi-targeted therapeutic potential in Alzheimer's disease” [https://doi.org/10.1016/j.ejmcr.2024.100154]). Exosomes are also being investigated for treatment delivery (“Natural acetylcholinesterase inhibitors: A multi-targeted therapeutic potential in Alzheimer's disease” [https://doi.org/10.1016/j.ejmcr.2024.100154]). The documents also mention existing drugs like huperzine A, galantamine, physostigmine, and rivastigmine used clinically to treat Alzheimer’s disease (“Natural acetylcholinesterase inhibitors: A multi-targeted therapeutic potential in Alzheimer's disease” [https://doi.org/10.1016/j.ejmcr.2024.100154]).\"}]"
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "chat"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.8"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
